Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lunsumio
Pharma
Roche’s bispecific-ADC combo keeps lymphoma at bay
The positive Lunsumio-Polivy readout could give Roche another shot at second-line LBCL as its Columvi contends with a regulatory setback.
Angus Liu
Jun 23, 2025 10:27am
ASH: Roche's subQ Lunsumio matches IV version in lymphoma
Dec 9, 2024 3:16pm
EU signs off on Regeneron's T-cell engager for 2 blood cancers
Aug 26, 2024 10:35am
AbbVie's Epkinly follows Roche's Lunsumio into FL
Jun 27, 2024 10:21am
JPM24: Roche touts its rebound in hematology, led by Hemlibra
Jan 9, 2024 4:26pm
ASH: Roche offers glimpse at Columvi-Polivy combo in DLBCL
Dec 11, 2023 7:00am
